Genmab reports 75% and 67% response rates in Phase 2 colorectal cancer trial

Genmab announced updated Phase 2 data for petosemtamab combined with chemotherapy in metastatic colorectal cancer. The trial showed an objective response rate of 75% in first‑line patients and 67% in second‑line patients, with an 81% response in first‑line left‑sided tumors. The results were presented at the ESMO Congress 2026 and support the ongoing global Phase 3 program. An investor update is scheduled for October 28.

Genmab’s shares rose 13% after the announcement, reflecting investor optimism about the drug’s potential. The data strengthen the rationale for the upcoming Phase 3 trials, which could drive future revenue growth if the drug receives regulatory approval.

  • 1Objective response rates were 75% in first‑line and 67% in second‑line metastatic colorectal cancer patients.
  • 2Response rate was 81% among first‑line patients with left‑sided tumors.
  • 3The analysis included 79 patients (45 first‑line, 34 second‑line).
  • 4Median follow‑up was 5.9 months in first‑line and 7.1 months in second‑line settings.
  • 5Petosemtamab‑related discontinuations occurred in 5% of the mFOLFOX6 group and 3% of the FOLFIRI group.
  • 6Genmab will host an investor update on October 28 at 5:00 p.m. CET/12:00 p.m. EDT.

Sources